So this is not a year for ASCO where we’re seeing a lot of breakthroughs in renal cell carcinoma. We are seeing, for example, a combination of lenvatinib plus immunotherapy in the front-line setting showing some promising data, which gives us some hope that perhaps lenvatinib is going to be an agent that’s going to make it into general usage as the clinical trials move forward...
So this is not a year for ASCO where we’re seeing a lot of breakthroughs in renal cell carcinoma. We are seeing, for example, a combination of lenvatinib plus immunotherapy in the front-line setting showing some promising data, which gives us some hope that perhaps lenvatinib is going to be an agent that’s going to make it into general usage as the clinical trials move forward. Beyond that really I think we’re just waiting for the late major readouts from the large phase 3 studies that are still underway at the moment.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
